News

Assessing the Effectiveness of Treatments of Personality Disorders in the Community

Catch up on coverage from the 63rd Annual Meeting of the American College of Neuropsychopharmacology in Phoenix, Arizona.

Anvesh Jalasutram, MD;Ayse Coskun, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

Patients with personality disorders would benefit from therapy regardless of modality, duration, or intensity.

"Wounds"

Richard M. Berlin, MD

Curating Depression Treatments Using Biomarker-Based Selection

"Here the body’s art conspires with destruction..."

Rudolf Uher, MUDr, PhD

Ibogaine Found to Reduce Mood Disorder and PTSD Symptoms, Consumption of Alcohol in Patients With Alcohol Use Disorder

What if biomarkers could tell you whether or not a depression treatment would work before a patient started?

Heidi Anne Duerr, MPH;Jason Tucciarone, MD, PhD;Jennifer Lissemore, PhD

Physical Activity, Lifestyle Factors, and the Aging Brain

How can Ibogaine help patients with Alcohol Use Disorder, specifically in veterans?

Heidi Anne Duerr, MPH;Helen Lavretsky, MD, MS

Gratitude for Taylor Swift

What effects do lifestyle factors have on brain aging and neuropsychiatic symptoms?

H. Steven Moffic, MD

A psychiatrist becomes a Swiftie after exploring the positive psychiatric attributes from her music.

Wounds

Richard M. Berlin, MD

SPN-820: Rapid-Acting Antidepressant Shows Promising Phase 2 Results

"Each wound contains its own beauty..."

Heidi Anne Duerr, MPH;Himanshu Upadhyaya, MBBS, MBA

Combating Negative Symptoms in Schizophrenia: Updated Treatment Approaches

Data presented at ACNP meeting demonstrated safety, tolerability, and efficacy for SPN-820 for MDD.

Michel Sabé, MD

Parliament House Passes Medical Aid in Dying Bill, Sparking Conversation and Controversy

Negative symptoms pose significant challenges for individuals with schizophrenia and their caregivers.

Megan McSweeney

Innovative Biomarker Research Focuses More at Controls

As the Terminally Ill Adults Bill moves through parliament, government representatives and doctors alike consider the effects legalization may have on patients of psychiatrists.

Heidi Anne Duerr, MPH;Arthur Caye, MD, PhD

Cognitive Impairment in Schizophrenia: How Machine Learning Is Helping

A poster at the ACNP Annual Meeting utilized a novel risk-informed case-control design to improve biomarker differentiation for ADHD.

Heidi Anne Duerr, MPH;Robert Chen, MD, PhD

Therapeutic Advances in Alzheimer Disease

Machine learning may help science better understand cognitive impairment in schizophrenia and improve prevention and patient care.

Gary W. Small, MD

Climate Change and Heat-Related Illness: Opportunities for Prevention in Psychiatric Practice

Do lifestyle interventions really work in Alzheimer disease and what are the underlying mechanisms? Learn more in this ACNP 2024 Annual Meeting session!

John Stea MD, MSPH;Zohaib Iqbal

Exploring Genetic Models in Schizophrenia Research: A Teaser From ACNP Annual Meeting

How can we prevent heat-related illness in patients with psychiatric disorders, who are more vulnerable to heat?

Heidi Anne Duerr, MPH;Thomas R. Kosten, MD

Psychopharmacology Innovations

Thomas R. Kosten, MD, shares thoughts on the latest schizophrenia genetic model research presented at the meeting.

John J. Miller, MD

Check out 2 new psychopharmacology innovations!

A Continued Evolution

John J. Miller, MD

Synaptic Dysfunction in Psychosis Explored at ACNP Meeting

Psychiatry: one of the most dynamic and rapidly evolving specialties in medicine.

Heidi Anne Duerr, MPH;M Belén Blasco, MD;Romina Mizrahi, MD, PhD

Research Points to Promise of Orexin Receptor Antagonists in Stress, AUDs

New research links reduced synaptic density,early psychosis, and cannabis use, offering insights into negative symptoms and potential interventions.

Heidi Anne Duerr, MPH

ACNP Meeting Highlights Bright Future for Psychiatry

Stephanie Gorka, PhD, shared findings at the ACNP Annual Meeting on orexin receptor agonists addressing AUDs.

Steven P. Levine, MD;Heidi Anne Duerr, MPH

ACNP Research Highlights With Thomas R. Kosten, MD

In highlighting recent advances and fostering collaboration and networking, the ACNP Annual Meeting helps usher in 2025 with hope and positivity.

Heidi Anne Duerr, MPH;Thomas R. Kosten, MD

From Stupor to Success: Managing Catatonia in Rural South Africa, A Case Report

Thomas R. Kosten, MD, shares insights on the ACNP meeting along with his excitement for potential new treatments.

Grace Lehnerdt, MD

A Year of Progress and Challenges

The presentation of catatonia can vary, making its management challenging, particularly in resource-limited settings in South Africa.

Mike Hennessy Jr

Beyond Abstinence: Other Clinically Meaningful Endpoints for Patients With Substance Use Disorders

Let's look back on a year marked by advancements and ongoing challenges in psychiatry.

F. Gerard Moeller, MD

Headline Psychiatric Views on the Weekend’s News: Pearl Harbor, Rebellions, Notre-Dame, and Wicked

While complete abstinence is a good goal, what other clinically meaningful endpoints are there for patients with substance use disorders? Learn more in this ACNP 2024 Annual Meeting session!

H. Steven Moffic, MD